The University of Chicago Header Logo

Connection

Piyush Agarwal to Humans

Back to Details
This is a "connection" page, showing publications Piyush Agarwal has written about Humans.
Piyush Agarwal
Connection Strength
0.523
Humans
  1. A 25-year perspective on advances in an understanding of the biology, evaluation, treatment and future directions/challenges of urothelial cancer. Urol Oncol. 2021 09; 39(9):528-547.
    View in: PubMed
    Score: 0.027
  2. Re: Pretransplant Solid Organ Malignancy and Organ Transplant Candidacy: A Consensus Expert Opinion Statement. Eur Urol. 2021 04; 79(4):552-553.
    View in: PubMed
    Score: 0.026
  3. Targeting Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor 2 (HER2) Expressing Bladder Cancer Using Combination Photoimmunotherapy (PIT). Sci Rep. 2019 02 14; 9(1):2084.
    View in: PubMed
    Score: 0.023
  4. Incidental bladder cancers found on multiparametric MRI of the prostate gland: a single center experience. Diagn Interv Radiol. 2018 Sep; 24(5):316-320.
    View in: PubMed
    Score: 0.022
  5. Bilateral Ureteroenteric Strictures: A Case of the "Reverse 7". Urology. 2018 Aug; 118:e3-e4.
    View in: PubMed
    Score: 0.021
  6. Lymph node dissection during radical cystectomy following prior radiation therapy: results from the SEER database. Int Urol Nephrol. 2018 Feb; 50(2):257-262.
    View in: PubMed
    Score: 0.021
  7. Protein kinase D inhibitor CRT0066101 suppresses bladder cancer growth in vitro and xenografts via blockade of the cell cycle at G2/M. Cell Mol Life Sci. 2018 03; 75(5):939-963.
    View in: PubMed
    Score: 0.021
  8. Current clinical trials in non-muscle invasive bladder cancer. Urol Oncol. 2017 08; 35(8):516-527.
    View in: PubMed
    Score: 0.020
  9. Epidermal Growth Factor Receptor (EGFR)-targeted Photoimmunotherapy (PIT) for the Treatment of EGFR-expressing Bladder Cancer. Mol Cancer Ther. 2017 10; 16(10):2201-2214.
    View in: PubMed
    Score: 0.020
  10. Genitourinary paraganglioma: Demographic, pathologic, and clinical characteristics in the surveillance, epidemiology, and end results database (2000-2012). Urol Oncol. 2017 07; 35(7):457.e9-457.e14.
    View in: PubMed
    Score: 0.020
  11. Proteomic analysis of proteome and histone post-translational modifications in heat shock protein 90 inhibition-mediated bladder cancer therapeutics. Sci Rep. 2017 03 15; 7(1):201.
    View in: PubMed
    Score: 0.020
  12. Managing noninvasive recurrences after definitive treatment for muscle-invasive bladder cancer or high-grade upper tract urothelial carcinoma. Curr Opin Urol. 2015 Sep; 25(5):468-75.
    View in: PubMed
    Score: 0.018
  13. Effect of metabolic syndrome on pathologic features of prostate cancer. Urol Oncol. 2013 Oct; 31(7):1054-9.
    View in: PubMed
    Score: 0.015
  14. Safety profile of robot-assisted radical prostatectomy: a standardized report of complications in 3317 patients. Eur Urol. 2011 May; 59(5):684-98.
    View in: PubMed
    Score: 0.013
  15. Role of PSA velocity in predicting pathologic upgrade for Gleason 6 prostate cancer. Urol Oncol. 2011 Jul-Aug; 29(4):372-7.
    View in: PubMed
    Score: 0.012
  16. Vattikuti Institute prostatectomy: technical modifications in 2009. Eur Urol. 2009 Jul; 56(1):89-96.
    View in: PubMed
    Score: 0.011
  17. Considerations on the use of diagnostic markers in management of patients with bladder cancer. World J Urol. 2008 Feb; 26(1):39-44.
    View in: PubMed
    Score: 0.010
  18. Emerging drugs for targeted therapy of bladder cancer. Expert Opin Emerg Drugs. 2007 Sep; 12(3):435-48.
    View in: PubMed
    Score: 0.010
  19. Functional and oncologic outcomes of prostate capsule-sparing radical cystectomy: A systematic review and meta-analysis. Urol Oncol. 2024 May; 42(5):121-132.
    View in: PubMed
    Score: 0.008
  20. Bladder-Preserving Trimodality Therapy With Capecitabine. Clin Genitourin Cancer. 2024 04; 22(2):476-482.e1.
    View in: PubMed
    Score: 0.008
  21. Flat intraurothelial lesions of the urinary bladder-do hyperplasia, dysplasia, and atypia of unknown significance need to exist as diagnostic entities? and how to handle in routine clinical practice. Mod Pathol. 2022 10; 35(10):1296-1305.
    View in: PubMed
    Score: 0.007
  22. Incidence of Preoperative Antibiotic Use and Its Association with Postoperative Infectious Complications after Radical Cystectomy. Urology. 2022 06; 164:169-177.
    View in: PubMed
    Score: 0.007
  23. Association between Industry Payments and Published Position on Use of Devices for the Treatment of Lower Urinary Tract Symptoms. Urology. 2022 01; 159:87-92.
    View in: PubMed
    Score: 0.007
  24. Autocrine signaling by receptor tyrosine kinases in urothelial carcinoma of the bladder. PLoS One. 2021; 16(7):e0241766.
    View in: PubMed
    Score: 0.007
  25. EZR-ROS1 fusion renal cell carcinoma mimicking urothelial carcinoma: report of a previously undescribed gene fusion in renal cell carcinoma. Virchows Arch. 2022 Feb; 480(2):487-492.
    View in: PubMed
    Score: 0.007
  26. Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee. J Immunother Cancer. 2020 11; 8(2).
    View in: PubMed
    Score: 0.006
  27. Pretransplant solid organ malignancy and organ transplant candidacy: A consensus expert opinion statement. Am J Transplant. 2021 02; 21(2):460-474.
    View in: PubMed
    Score: 0.006
  28. Preexisting melanoma and hematological malignancies, prognosis, and timing to solid organ transplantation: A consensus expert opinion statement. Am J Transplant. 2021 02; 21(2):475-483.
    View in: PubMed
    Score: 0.006
  29. Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors. J Clin Oncol. 2020 11 01; 38(31):3672-3684.
    View in: PubMed
    Score: 0.006
  30. Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial. Lancet Oncol. 2020 08; 21(8):1099-1109.
    View in: PubMed
    Score: 0.006
  31. Multiresolution Application of Artificial Intelligence in Digital Pathology for Prediction of Positive Lymph Nodes From Primary Tumors in Bladder Cancer. JCO Clin Cancer Inform. 2020 04; 4:367-382.
    View in: PubMed
    Score: 0.006
  32. Ferumoxytol-Enhanced MR Lymphography for Detection of Metastatic Lymph Nodes in Genitourinary Malignancies: A Prospective Study. AJR Am J Roentgenol. 2020 01; 214(1):105-113.
    View in: PubMed
    Score: 0.006
  33. Identification of Neoantigen-Reactive Tumor-Infiltrating Lymphocytes in Primary Bladder Cancer. J Immunol. 2019 06 15; 202(12):3458-3467.
    View in: PubMed
    Score: 0.006
  34. ICUD-SIU International Consultation on Bladder Cancer 2017: management of non-muscle invasive bladder cancer. World J Urol. 2019 Jan; 37(1):51-60.
    View in: PubMed
    Score: 0.005
  35. Integrative analysis of the epigenetic basis of muscle-invasive urothelial carcinoma. Clin Epigenetics. 2018; 10:19.
    View in: PubMed
    Score: 0.005
  36. The Sunshine Act and oncology: Lessons learned from urology. Semin Oncol. 2017 08; 44(4):265-266.
    View in: PubMed
    Score: 0.005
  37. Advances in medical imaging for the diagnosis and management of common genitourinary cancers. Urol Oncol. 2017 07; 35(7):473-491.
    View in: PubMed
    Score: 0.005
  38. Development, validation and clinical application of Pelvic Lymphadenectomy Assessment and Completion Evaluation: intraoperative assessment of lymph node dissection after robot-assisted radical cystectomy for bladder cancer. BJU Int. 2017 06; 119(6):879-884.
    View in: PubMed
    Score: 0.005
  39. Urinary Bladder Paragangliomas: How Immunohistochemistry Can Assist to Identify Patients With SDHB Germline and Somatic Mutations. Am J Surg Pathol. 2015 Nov; 39(11):1488-92.
    View in: PubMed
    Score: 0.005
  40. Trimodality therapy in bladder cancer: who, what, and when? Urol Clin North Am. 2015 May; 42(2):169-80, vii.
    View in: PubMed
    Score: 0.004
  41. Association of urinary bladder paragangliomas with germline mutations in the SDHB and VHL genes. Urol Oncol. 2015 Apr; 33(4):167.e13-20.
    View in: PubMed
    Score: 0.004
  42. Preliminary evaluation of urinary soluble Met as a biomarker for urothelial carcinoma of the bladder. J Transl Med. 2014 Oct 21; 12:199.
    View in: PubMed
    Score: 0.004
  43. New facial papules in a 66-year-old woman with bladder cancer. J Am Acad Dermatol. 2014 Dec; 71(6):1250-5.
    View in: PubMed
    Score: 0.004
  44. Multimodal management of muscle-invasive bladder cancer. Curr Probl Cancer. 2014 May-Jun; 38(3):80-108.
    View in: PubMed
    Score: 0.004
  45. Examining the management of muscle-invasive bladder cancer by medical oncologists in the United States. Urol Oncol. 2014 Jul; 32(5):637-44.
    View in: PubMed
    Score: 0.004
  46. Clinical significance of ureteric 'skip lesions' at the time of radical cystectomy: the M.D. Anderson experience and literature review. BJU Int. 2014 May; 113(5b):E28-33.
    View in: PubMed
    Score: 0.004
  47. Targeted therapies in urothelial carcinoma. Curr Opin Oncol. 2014 May; 26(3):305-20.
    View in: PubMed
    Score: 0.004
  48. Analysis of intracorporeal compared with extracorporeal urinary diversion after robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. Eur Urol. 2014 Feb; 65(2):340-7.
    View in: PubMed
    Score: 0.004
  49. The impact of hospital volume, residency, and fellowship training on perioperative outcomes after radical prostatectomy. Urol Oncol. 2014 Jan; 32(1):29.e13-20.
    View in: PubMed
    Score: 0.004
  50. Reply from authors re: Manfred P. Wirth, Johannes Huber. What really matters is rarely measured: outcome of routine care and patient-reported outcomes. Eur Urol 2013;64:58-9: robot-assisted versus open radical cystectomy: beating a dead horse. Eur Urol. 2013 Jul; 64(1):60-1.
    View in: PubMed
    Score: 0.004
  51. Impact of surgeon and volume on extended lymphadenectomy at the time of robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium (IRCC). BJU Int. 2013 Jun; 111(7):1075-80.
    View in: PubMed
    Score: 0.004
  52. Complications after robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. Eur Urol. 2013 Jul; 64(1):52-7.
    View in: PubMed
    Score: 0.004
  53. Disparities in access to care at high-volume institutions for uro-oncologic procedures. Cancer. 2012 Sep 15; 118(18):4421-6.
    View in: PubMed
    Score: 0.003
  54. Outcome of patients with bladder cancer with pN+ disease after preoperative chemotherapy and radical cystectomy. Urology. 2009 Jan; 73(1):147-52.
    View in: PubMed
    Score: 0.003
  55. Lymph node density is superior to TNM nodal status in predicting disease-specific survival after radical cystectomy for bladder cancer: analysis of pooled data from MDACC and MSKCC. J Clin Oncol. 2008 Jan 01; 26(1):121-6.
    View in: PubMed
    Score: 0.003
  56. Targeted therapies in bladder cancer--an update. Urol Oncol. 2007 Sep-Oct; 25(5):433-8.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.